Drug offers hope to obsessives
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ELIZABETH NASH
Madrid
Sufferers from obsessive illnesses such as binge eating, sexual compulsions, kleptomania, shopping mania and the so-called "disease of imagined ugliness" may be helped by a medicine long available in Britain that is often prescribed for depression.
The drug fluvoxamine, sold in Britain as Faverin, regulates one of the brain's chemical messengers, serotonin, which is used in eating, sleeping and sex, and is thought to control states of consciousness and mood. Depression is linked to a deficiency of serotonin, and research suggests it may be linked to obsessive disorders.
These disorders, which also include pathological gambling and intermittent explosive behaviour, may produce an initial high followed by strong feelings of guilt and shame. This means they are often hidden and go undiagnosed, American scientists said yesterday.
Dr Eric Hollander, professor of psychiatry at New York's Mount Sinai School of Medicine, told a symposium in Madrid that many of these behavioural disorders had biological origins and that fluv oxamine often helped where psychotherapy had failed.
"Obsessive-compulsive disorders are extremely common, some affecting up to 10 per cent of the population, and it is a great relief for patients to know that they are not alone, and they are not going crazy. Now help is available for the first time."
He added that in pilot trials, compulsive shoppers, pathological gamblers and kleptomaniacs had responded well to fluvoxamine treatment.
Katharine Phillips, a specialist in Body Dysmorphic Disorder, the disease of imagined ugliness, said "It is easy to trivialise these disorders, but they are very serious. BDD can torment sufferers, take over their lives and lead them to suicide. It doesn't go away by just telling people they look fine."
Sufferers would spend up to eight hours a day checking and rechecking their perceived defects in front of a mirror. But in a trial, Dr Phillips found 70 per cent of her patients felt better or much better after taking fluvoxamine for four months.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments